Conference Call & Webcast Presentation October 23, 2025 Disclaimer Forward Looking Statements Certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by or include words such as "will", "expect", "intends" or other similar words, phrases or expressions. These statements relate to future events or our future financial or ...

Investor Presentation October 23, 2025 WYNDHAM HOTELS & RESORTS La Quinta Inn & Suites by Wyndham Phoenix, Arizona, USA Opened August 2025 Introduction to Wyndham Hotels & Resorts Largest hotel franchisor worldwide(a) Leading brands in the resilient select-service segment Asset-light business model generating significant free cash flow Primarily leisure-focused, "drive to" portfolio of hotels ~8.300" Hotels ~855,000~ Current Rooms ~257,000 ~70% Leisure Guest Mix Data is approximated as of September 30, 2025 ...

Vopimetostat (TNG462) Overview - Vopimetostat is an oral, once-a-day, MTAP-selective PRMT5 inhibitor with a potential best-in-class safety profile[7] - Key indications for development include pancreatic cancer (~20,000 patients/yr), lung cancer (~22,000 patients/yr), and histology agnostic cancers (~20,000 patients/yr) in the US[7] - A pivotal study in second-line (2L) pancreatic cancer is planned to initiate in 2026, with the potential to be first-to-market in 2L MTAP-del pancreatic cancer[7] Clinical Trial Data and Efficacy - Vopimetostat demonstrated an overall response rate (ORR) of 27% across cancer types, suggesting it could be best-in-class[13,16,18] - In 2L MTAP-del pancreatic cancer, the median progression-free survival (mPFS) was 7.2 months, with an ORR of 25%, supporting the planned pivotal study start in 2026[13,34] - The histology agnostic cohort (excluding sarcoma, pancreatic, and lung cancer) showed a 49% ORR and an mPFS of 9.1 months[13,51,53] Safety and Tolerability - Vopimetostat has a potential best-in-class safety and tolerability profile, with approximately 8% dose reduction and no drug-related dose discontinuations[13,25] Combination Studies and Future Plans - Ongoing combination study of vopimetostat + RAS(ON) inhibitors in 2L+ MTAP-del pancreatic and lung cancer patients, with expansion to first line (1L) cohort planned[13,43,45] - Lung cancer cohort is fully enrolled (n=41), with an update planned for 2026[13,48]

C O N V E N I E N C E A U T O M O T I V E R E T A I L CORPORATE PROFILE and SUPPLEMENTAL INFORMATION OCTOBER 2025 SAFE HARBOR STATEMENTS Forward Looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are statements that relate to management's expectations or beliefs, future plans and strategies, future financial performance and similar expressions concerning matters that are not historic ...

3Q25 Update (Nasdaq: BHRB) October 2025 1 Cautionary Statement Regarding Forward-Looking Information This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the beliefs, goals, intentions, and expectations of the Company regarding revenues, earnings, earnings per share, loan production, asset qua ...

I N V E S T O R P R E S E N T A T I O N F I R S T Q U A R T E R F I S C A L 2 0 2 6 October 23, 2025 Forward Looking Statements & Financial Measures This presentation may include certain "forward-looking statements," which are made in good faith by Kearny Financial Corp. (the "Company") pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, such as statements of the Company's plans, objectives ...

Q3 2025 Earnings Presentation October 23, 2025 © 2025 TechnipFMC. All rights reserved. The information contained in this document is company confidential and proprietary property of TechnipFMC and its affiliates. It is to be used only for the benefit of TechnipFMC and may not be distributed, transmitted, reproduced, altered, or used for any purpose without the express written consent of TechnipFMC. Disclaimer Forward-looking statements This communication contains "forward-looking statements" as defined in S ...

volatility of the Company's share price; risks related to currency fluctuations and foreign exchange controls; the potential impact of increased competition in the markets within which the Company operates, including competitive actions by other companies; the failure to respond to change and advancements in technology; risks relating to consolidation among commercial exhibitors and studios; risks related to brand extensions and new business initiatives; conditions in the in-home and out-of- home entertainm ...

FISCAL FOURTH QUARTER AND FISCAL 2025 HIGHLIGHTS October 22, 2025 PLEXUS CONFIDENTIAL SAFE HARBOR AND FAIR DISCLOSURE STATEMENT Some of the statements made and information provided during our call as well as information included in the supporting materials will be forward looking statements, including, without limitation, those regarding revenue, gross margin, selling and administrative expense, operating margin, other income and expense, taxes, cash cycle, capital allocation and future business outlook. Fo ...

ALTISOURCE PORTFOLIO SOLUTIONS THIRD QUARTER 2025 SUPPLEMENTARY INFORMATION © 2025 Altisource All Rights Reserved. AUGUST 2022 Furthermore, we believe the exclusion of more significant non-operational items enables comparability to prior period performance and trend analysis. DISCLAIMER This presentation contains forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements include all statements that are not historical fact, including statements that relate t ...